keyword
MENU ▼
Read by QxMD icon Read
search

HBV IFN

keyword
https://www.readbyqxmd.com/read/29325291/-hepatitis-b-core-antigen-promotes-invasion-of-hepatocellular-carcinoma-cell-line-hepg2-2-15-via-toll-like-receptor-4
#1
H R Hou, Y Kang, Y K Li, Y L Zeng, J F Wei, G G Ding, Z Peng, J Shang
Objective: To investigate the effect of hepatitis B core antigen (HBcAg) in promoting the invasion of hepatitis B virus (HBV)-related hepatocellular carcinoma cell line HepG2.2.15 and the role of Toll-like receptor 4 (TLR4) in the mechanism. Methods: TLR4 mRNA and protein expression in HepG2 cells and HepG2.2.15 cells was measured by reverse transcription real-time PCR and Western blot analysis, respectively. HepG2.2.15 cells were transfected with TLR4 specific small interfering RNA (siRNA) to silence TLR4 expression, and stimulated by recombinant HBcAg in culture...
December 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29325289/-optimal-treatment-regimen-for-patients-with-hbeag-positive-chronic-hepatitis-b-after-suboptimal-response-to-24-weeks-of-peg-ifn-%C3%AE-2a
#2
X D Luo, X P Chen, X F Chen
Objective: To investigate the optimal treatment regimen for patients with HBeAg-positive chronic hepatitis B (CHB) after suboptimal response to 24 weeks of pegylated interferon (Peg-IFN) α-2a. Methods: A total of 188 patients with HBeAg-positive CHB who had suboptimal response to 24 weeks of Peg-IFN α-2a were randomly divided into entecavir group (n = 93) and telbivudine group (n = 95). The two groups received entecavir 0.5 mg/d and telbivudine 0.6 g/d, respectively, for 208 weeks. After 208 weeks of treatment, the following indices were assessed: HBeAg clearance rate and seroconversion rate, hepatitis B virus (HBV) DNA clearance rate (HBV DNA < 500 IU/ml), safety, and drug resistance rate...
December 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29314573/higher-efficacy-of-pegylated-interferon-alpha-2b-add-on-therapy-in-hbeag-positive-chronic-hepatitis-b-patients-on-tenofovir-monotherapy
#3
Ankur Jindal, Ashish Kumar Vyas, Devesh Kumar, Guresh Kumar, Manoj Kumar Sharma, Shiv Kumar Sarin
BACKGROUND: Monotherapy with Peg-IFNα or nucleos(t)ide analogues(NA) currently approved for treating chronic hepatitis B(CHB) have limited efficacy. Studies on combination of Peg-IFN-α/NA have shown conflicting results. We investigated whether sequential adding-on Peg-IFNα to tenofovir enhances serological response rates. METHODS: Treatment naïve, HBeAg-positive CHB patients with moderately elevated ALT(48 to 200IU/mL) were started on tenofovir(300 mg/day) and enrolled at week 12 in 1:1 ratio to either receive Peg-IFNα2b add-on(1...
January 4, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29303483/uptake-of-tenofovir-based-antiretroviral-therapy-among-hiv-hbv-coinfected-patients-in-the-eurosida-study
#4
Lars Peters, Amanda Mocroft, Daniel Grint, Santiago Moreno, Alexandra Calmy, Djordje Jevtovic, Helen Sambatakou, Karine Lacombe, Stephane De Wit, Jürgen Rockstroh, Jelena Smidt, Igor Karpov, Anna Grzeszczuk, Vesnadarjan Haziosmanovic, Magnus Gottfredsson, Roxana Radoi, Elena Kuzovatova, Chloe Orkin, Anna Lisa Ridolfo, Jose Zapirain, Jens Lundgren
BACKGROUND: According to guidelines all HIV/HBV co-infected patients should receive tenofovir-based combination antiretroviral therapy (cART). We aimed to investigate uptake and outcomes of tenofovir-based cART among HIV/HBV patients in the EuroSIDA study. METHODS: All HBsAg+ patients followed up after 1 March 2002 were included. Changes in the proportion taking tenofovir-based cART over time were described. Poisson regression was used to investigate the relationship between tenofovir use and clinical events...
January 5, 2018: Antiviral Therapy
https://www.readbyqxmd.com/read/29290826/a-cell-penetrating-whole-molecule-antibody-targeting-intracellular-hbx-suppresses-hepatitis-b-virus-via-trim21-dependent-pathway
#5
Jun-Fang Zhang, Hua-Long Xiong, Jia-Li Cao, Shao-Juan Wang, Xue-Ran Guo, Bi-Yun Lin, Ying Zhang, Jing-Hua Zhao, Ying-Bin Wang, Tian-Ying Zhang, Quan Yuan, Jun Zhang, Ning-Shao Xia
Rationale: Monoclonal antibodies (mAbs) mostly targeting extracellular or cell surface molecules have been widely used in the treatment of various diseases. However, mAbs cannot pass through the cell membrane as efficiently as small compounds, thus limiting their use against intracellular targets. Methods to shuttle antibodies into living cells may largely expand research and application in areas based on mAbs. Hepatitis B virus X protein (HBx) is an important intracellular multi-functional viral protein in the life cycle of hepatitis B virus (HBV)...
2018: Theranostics
https://www.readbyqxmd.com/read/29285141/interferon-%C3%AE-inhibits-cell-migration-and-invasion-and-induces-the-expression-of-antiviral-proteins-in-huh-7-cells-transfected-with-hepatitis-b-virus-x-gene-expressing-lentivirus
#6
Qian Yang, Xiao-Peng Li, Yuan-Bin Zhong, Tian-Xin Xiang, Lun-Li Zhang
Hepatitis B virus (HBV) X protein (HBx) serves an important role in HBV infection and the development of HBV-related liver cancer. Interferon-α (IFN-α) is used to treat patients with HBV; however, the role of IFN-α in the development of HBV-related liver cancer remains unclear. The present study established a new HBV-related liver cancer model (Huh-7-HBx) by transfecting the hepatoma cell line Huh-7, with HBx-expressing lentivirus. Following IFN-α treatment, cell viability, migration and invasion, as well as the expression of antiviral proteins in Huh-7-HBx, were subsequently determined...
December 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/29247725/toll-like-receptor-7-agonist-gs-9620-induces-prolonged-inhibition-of-hbv-via-a-type-i-interferon-dependent-mechanism
#7
Congrong Niu, Li Li, Stephane Daffis, Julie Lucifora, Marc Bonnin, Sarah Maadadi, Eduardo Salas, Ruth Chu, Hilario Ramos, Christine M Livingston, Rudolf K Beran, Abhishek V Garg, Scott Balsitis, David Durantel, Fabien Zoulim, William E Delaney, Simon P Fletcher
BACKGROUND & AIMS: GS-9620, an oral agonist of toll-like receptor 7 (TLR7), is in clinical development for the treatment of chronic hepatitis B (CHB). GS-9620 was previously shown to induce prolonged suppression of serum viral DNA and antigens in the woodchuck and chimpanzee models of CHB. Here we investigated the molecular mechanisms that contribute to the antiviral response to GS-9620 using in vitro models of hepatitis B virus (HBV) infection. METHODS: Cryopreserved primary human hepatocytes (PHH) and differentiated HepaRG (dHepaRG) cells were infected with HBV and treated with GS-9620, conditioned media from human peripheral blood mononuclear cells (PBMCs) treated with GS-9620 (GS-9620 conditioned media; GS-9620-CM), or other innate immune stimuli...
December 13, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29247529/serum-m2bpgi-level-is-a-novel-predictive-biomarker-for-the-responses-to-pegylated-interferon-%C3%AE-treatment-in-hbeag-positive-chronic-hepatitis-b-patients
#8
Ming-Yu Zhu, Pei-Zhan Chen, Jing Li, De-Min Yu, Dao Huang, Xue-Juan Zhu, Yue Han, Jie Chen, Wei Huang, Yong-Yan Chen, Qi-Ming Gong, Jie-Hong Jiang, Dong-Hua Zhang, Yan Zhang, Ji-Ming Zhang, Xin-Xin Zhang
Serum Mac-2-binding protein glycosylation isomer (M2BPGi) level was found to be a useful prognostic marker for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients treated with nucleoside/nucleotide analogs (NUCs) therapy, and the aim of our study is to evaluate the clinical implementation of M2BPGi level in the prediction of antiviral responses to pegylated-interferon-α (PEG-IFN-α) treatment in HBeAg-positive CHB patients. Ninety-six CHB patients who received PEG-IFN-α treatment for at least 48 weeks were recruited...
December 16, 2017: Journal of Medical Virology
https://www.readbyqxmd.com/read/29235226/reduced-therapeutic-effect-of-antiviral-drugs-in-patients-with-hepatitis-b-virus-reactivation-after-hematopoietic-stem-cell-transplantation
#9
Masamichi Kimura, Koji Nishikawa, Hisashi Sakamaki, Masashi Mizokami, Kiminori Kimura
BACKGROUND: Patients with resolved Hepatitis B virus (HBV) infection following hematopoietic stem cell transplantation (HSCT) are potentially at high risk of HBV reactivation. Although anti-viral drug therapy is recommended when HBV DNA reappears in the serum, drug efficacy after HBV reactivation remains unclear. METHODS: Host immune response against HBV was investigated via immunological analyses at 12 months after entecavir (ETV) treatment in six HSCT-treated and five non-HSCT-treated patients with HBV reactivation, and 18 patients with chronic hepatitis B (CHB)...
December 13, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29226133/circulating-interferon-%C3%AE-3-responsiveness-to-hbv-vaccination-and-hbv-hcv-infections-in-haemodialysis-patients
#10
Alicja E Grzegorzewska, Monika K Świderska, Adrianna Mostowska, Paweł P Jagodziński
The IFN-λ3 gene (IFNL3) plays a role in HCV clearance. We investigated circulating IFN-λ3 and IFNL3 SNPs in haemodialysis patients who differed in their response to HBV vaccination and their HBV/HCV infection status. In 201 patients, plasma IFN-λ3 was determined using ELISA. IFNL3 SNPs (rs12979860, rs8099917) were genotyped using HRM analysis. Differences in IFN-λ3 levels were shown between responders and nonresponders to HBV vaccination and between HBsAg-positive patients and those who developed anti-HBs after infection and became HBsAg negative...
2017: BioMed Research International
https://www.readbyqxmd.com/read/29220492/hbv-derived-synthetic-long-peptide-can-boost-cd4-and-cd8-t-cell-responses-in-chronic-hbv-patients-ex-vivo
#11
Yingying Dou, Nadine van Montfoort, Aniek van den Bosch, Robert A de Man, Gijs G Zom, Willem-Jan Krebber, Cornelis J M Melief, Sonja I Buschow, Andrea M Woltman
Background: Vaccination with Synthetic Long Peptides (SLP ®) is a promising new treatment strategy for chronic HBV (CHB). SLP can induce broad T cell responses for all HLA types. Here we investigated the ability of a prototype HBV-core (HBc)-sequence-derived SLP to boost HBV-specific T cells in CHB patients ex vivo. Methods: HBc-SLP was used to assess cross-presentation by monocyte-derived DC(moDC) and BDCA1+ blood myeloid DC (mDC) to engineered HBV-specific CD8+ T cells...
December 6, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29214184/protective-effects-of-moringa-oleifera-on-hbv-genotypes-c-and-h-transiently-transfected-huh7-cells
#12
Sina Feustel, Fabiola Ayón-Pérez, Ana Sandoval-Rodriguez, Roberto Rodríguez-Echevarría, Homero Contreras-Salinas, Juan Armendáriz-Borunda, L V Sánchez-Orozco
Chronic hepatitis B infection treatment implicates a long-lasting treatment. M. oleifera extracts contain compounds with antiviral, antioxidant, and antifibrotic properties. In this study, the effect of M. oleifera was evaluated in Huh7 cells expressing either HBV genotypes C or H for the antiviral, antifibrotic, anti-inflammatory, and antioxidative responses. Huh7 cells were treated with an aqueous extract of M. oleifera (leaves) at doses of 0, 30, 45, or 60 μg/mL. The replicative virus and TGF-β1, CTGF, CAT, IFN-β1, and pgRNA expressions were measured by real time...
2017: Journal of Immunology Research
https://www.readbyqxmd.com/read/29181338/interleukin-35-suppresses-antiviral-immune-response-in-chronic-hepatitis-b-virus-infection
#13
Xue Shao, Jingting Ma, Shengnan Jia, Lanlan Yang, Wudong Wang, Zhenjing Jin
The mechanisms of hepatitis B virus (HBV) persistent infection are not completely understood. Interleukin (IL)-35, which is a newly identified cytokine belongs to IL-12 family, has been demonstrated to induce immunotolerance. Thus, the aim of current study was to investigate the role of IL-35 during chronic HBV infection. A total of 61 patients with chronic HBV infection [37 chronic hepatitis B (CHB) and 24 asymptomatic HBV carriers (ASC)] and 20 healthy individuals were enrolled. IL-35 concentration as well as the modulatory function of IL-35 on CD4+CD25+CD127dim/- regulatory T cells (Tregs) and on HBV antigen-specific CD8+ T cells was investigated...
2017: Frontiers in Cellular and Infection Microbiology
https://www.readbyqxmd.com/read/29179600/nanovaccine-for-immunotherapy-and-reduced-hepatitis-b-virus-in-humanized-model
#14
Hitesh Kumar Dewangan, Tarun Pandey, Sanjay Singh
Chronic Hepatitis B Virus (HBV) infections are severe with weak antiviral immune responses. The lack of an appropriate small animal model for chronic hepatitis, a major hurdle for studying the immunotolerance and immunopathogenesis induced by hepatitis B viral (HBV) infection. In this study, for enhancing the antibody production efficiency the prepared polymeric HBsAg-loaded nanoparticles (nanovaccine) will be tested in immune-deficit mice, which suffer from chronic Hepatitis B virus. Vaccination of Balb/c mice by this prepared nanoparticles that were engrafted with peripheral blood mononuclear cells (PBMCs), which was already lethally irradiated and transplanted by the bone marrow of NOD (knockout mice) mice...
November 27, 2017: Artificial Cells, Nanomedicine, and Biotechnology
https://www.readbyqxmd.com/read/29131246/study-on-the-distribution-of-cd8-memory-t-cell-subsets-and-ifn-%C3%AE-level-during-the-spontaneous-clearance-of-hepatitis-b-virus-in-patients-with-chronic-hepatitis-b-virus-infection
#15
X-J Ma, X-F Chen, W-L Chen, R Chen, J Huang, X-D Luo, J-Y Liao, X-P Chen
OBJECTIVE: To study the alteration of CD8+ memory T cell subsets under different immune statuses during the spontaneous clearance of hepatitis B virus (HBV) in Chinese patients with chronic HBV infection. PATIENTS AND METHODS: We analyzed Chinese patients with chronic HBV infection including 10 patients with Hepatitis B surface Antigen (HBsAg) spontaneous seroconversion, 25 patients with Hepatitis B virus e Antigen (HBeAg) spontaneous seroconversion, 25 patients with chronic hepatitis B (CHB), and 25 chronic HBV carriers...
October 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29111266/hepatoprotective-and-inhibiting-hbv-effects-of-polysaccharides-from-roots-of-sophora-flavescens
#16
Hua Yang, Zhenhua Zhou, Lifang He, Hao Ma, Wensheng Qu, Jiye Yin, Mengfan Jia, Xiunan Zhao, Junjie Shan, Yueqiu Gao
Roots of Sophora flavescens is an important herbal medicine for treatment of HBV and hepatic carcinoma in China. Alkaloids in the root were well known for exhibiting good hepato-protective and anti-HBV effects. However, polysaccharides as main components in the root remained unknown. In the studies, we investigated the chemical features and hepatoprotective effects of Sophora flavescens polysaccharides (SFP-100 and its active fractions) with ConA-induced hepatitis mice, human liver LO2 cells and HepG2.2.15 cells...
October 27, 2017: International Journal of Biological Macromolecules
https://www.readbyqxmd.com/read/29091327/unconventional-t-cells-in-chronic-hepatitis-b-patients-on-long-term-suppressive-therapy-with-tenofovir-followed-by-a-peg-ifn-add-on-strategy-a-randomized-study
#17
Elvira Stefania Cannizzo, Camilla Tincati, Francesca Binda, Paola Ronzi, Federico Angelo Cazzaniga, Spinello Antinori, Antonella d'Arminio Monforte, Giulia Marchetti, Laura Milazzo
HBV eradication in Chronic Hepatitis B (CHB) subjects is rarely achieved with either nucleos(t)ide analogues (NA) or pegylated interferon (Peg-IFN), which both have a limited effect in restoring immune responses. 30 CHB subjects on long-term treatment with tenofovir (TDF) and HBV suppression were enrolled and randomized 1:2 to either receive Peg-IFN-α-2a add-on therapy or continue TDF alone. We studied γδT and iNKT frequency and function (by flow cytometry) at baseline, at 12 weeks and 12 weeks after the end of treatment...
November 1, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29082649/peginterferon-is-preferable-to-entecavir-for-prevention-of-unfavourable-events-in-patients-with-hbeag-positive-chronic-hepatitis-b-a-five-year-observational-cohort-study
#18
S-Y Li, H Li, Y-L Xiong, F Liu, M-L Peng, D-Z Zhang, H Ren, P Hu
At present, the long-term effects of pegylated interferon-α (PEG-IFN-α) and entecavir (ETV) are controversial. Studies directly compared the long-term outcomes of these two drugs have not been completed. This study was designed to compare the clinical outcomes of PEG-IFN-α vs ETV therapy in Chinese patients with chronic HBV infection. From September 2008 to December 2016, a large, observational, open-label, prospective cohort study of HBeAg-positive patients with CHB who received PEG-IFN-α or ETV therapy was carried out at the Second Affiliated Hospital of Chongqing Medical University...
November 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29080231/eno1-alpha-enolase-regulates-hbv-replication-through-suppression-of-the-ifn-signaling-pathway
#19
Ding Xiang-Chun, Yang Xiao-Qing, Yan Ting-Ting, Lu Zhen-Hui, Liu Xiao-Yan, Luo Xia, Hu Yan-Chao, Yang Yi-Xuan, Ma Li-Na
Persistent chronic infection with hepatitis B virus (HBV) is a major risk factor for the development of HBV-related diseases. The molecular mechanisms that underlie HBV infection and associated carcinogenesis are not fully understood. The aim of this study was to explore the role of ENO1 in HBV replication processes.Here,we examined ENO1 expression levels in HBV-infected and non-HBV-infected liver tissues and cells by Western blot analysis, real-time PCR, and immunohistochemistry. In addition, HBsAg and HBeAg in the media of transfected HepG2...
October 27, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29079518/efficacy-of-nvr-3-778-alone-and-in-combination-with-pegylated-interferon-vs-entecavir-in-upa-scid-mice-with-humanized-livers-and-hbv-infection
#20
Klaus Klumpp, Takashi Shimada, Lena Allweiss, Tassilo Volz, Marc Lütgehetmann, G Hartman, Osvaldo A Flores, Angela M Lam, Maura Dandri
BACKGROUND & AIMS: NVR3-778 is a capsid assembly modulator in clinical development. We determined the in vivo anti-viral efficacy and effects on innate and endoplasmic reticulum (ER) stress responses of NVR3-778 alone or in combination with pegylated interferon alpha (peg-IFN) and compared with entecavir. METHODS: We performed 2 studies, with a total of 61 uPA/SCID mice with humanized livers. Mice were infected with a HBV genotype C preparation; we waited 8 weeks for persistent infection of the human hepatocytes in livers of mice...
October 24, 2017: Gastroenterology
keyword
keyword
121045
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"